Cargando…

Safety and efficacy of plerixafor dose escalation for the mobilization of CD34(+) hematopoietic progenitor cells in patients with sickle cell disease: interim results

Gene therapy for sickle cell disease is limited by the yield of hematopoietic progenitor cells that can be harvested for transduction or gene editing. We therefore performed a phase I dose-escalation study of the hematopoietic progenitor cell mobilizing agent plerixafor to evaluate the efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boulad, Farid, Shore, Tsiporah, van Besien, Koen, Minniti, Caterina, Barbu-Stevanovic, Mihaela, Fedus, Sylvie Wiener, Perna, Fabiana, Greenberg, June, Guarneri, Danielle, Nandi, Vijay, Mauguen, Audrey, Yazdanbakhsh, Karina, Sadelain, Michel, Shi, Patricia A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927989/ https://www.ncbi.nlm.nih.gov/pubmed/29419425 http://dx.doi.org/10.3324/haematol.2017.187047

Ejemplares similares

Coronavirus Infection in Hematopoietic Stem Cell Transplant Recipients
por: Eichenberger, Emily, et al.
Publicado: (2017)

Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan–Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation
por: Patel, Khilna, et al.
Publicado: (2016)

Plerixafor
por: Slater, Susan
Publicado: (2012)

2501. Impact of Influenza A and B Infection on Stem Cell Transplant Patients During the 2017–2018 Season at a Single Center
por: Pyai, Khin Sandar, et al.
Publicado: (2018)

2695. Pneumocystis jirovecii Pneumonia in the Era of Effective Prophylaxis Following Hematopoietic Stem Cell Transplant
por: Drelick, Alexander Christian, et al.
Publicado: (2019)

Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor
por: Uchida, Naoya, et al.
Publicado: (2020)

Incidence, significance, and persistence of human coronavirus infection in hematopoietic stem cell transplant recipients
por: Eichenberger, Emily M., et al.
Publicado: (2018)

Elucidating parasite and host-cell factors enabling Babesia infection in sickle red cells under hypoxic/hyperoxic conditions
por: Beri, Divya, et al.
Publicado: (2022)

Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion
por: Lagresle-Peyrou, Chantal, et al.
Publicado: (2018)

Plerixafor for autologous CD34(+) cell mobilization
por: Salman, Huda, et al.
Publicado: (2011)

Severe delayed hemolytic transfusion reaction due to anti-Fy3 in a patient with sickle cell disease undergoing red cell exchange prior to hematopoietic progenitor cell collection for gene therapy
por: Stone, Elizabeth F., et al.
Publicado: (2020)

Efficacy of Afternoon Plerixafor Administration for Stem Cell Mobilization
por: El Rahi, Cynthia, et al.
Publicado: (2018)

Plerixafor use for peripheral blood stem cell mobilization in Korea
por: Kim, Seok Jin, et al.
Publicado: (2013)

Addition of plerixafor in poorly mobilized allogeneic stem cell donors
por: Zhuang, Lefan, et al.
Publicado: (2022)

Predictors of Covid-19 Vaccination Response After In-Vivo T-Cell–Depleted Stem Cell Transplantation
por: Chaekal, Ok-kyong, et al.
Publicado: (2022)

532. COVID-19 Pneumonia in Patients with Hematologic Malignancies – A Report from the US Epicenter
por: Plate, Markus, et al.
Publicado: (2020)

S114: FEASIBILITY OF HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR PATIENTS WITH SEVERE SICKLE CELL DISEASE WITH END-STAGE RENAL DISEASE (ESRD) ON HEMODIALYSIS
por: Gomez Arteaga, A, et al.
Publicado: (2022)

Case Study in Refractory Non-Hodgkin's Lymphoma: Successful Treatment with Plerixafor
por: Azim, Hamdy Abdel, et al.
Publicado: (2011)

Plerixafor in the Treatment of Stem Cell Mobilization Failure; First Experience in Iran
por: Mehdizadeh, Mahshid, et al.
Publicado: (2013)

Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor
por: Fadini, Gian Paolo, et al.
Publicado: (2015)

Use of Plerixafor to Mobilize a Healthy Donor Infected with Influenza A
por: Yeral, Mahmut, et al.
Publicado: (2018)

P2 3-year observation study of Plerixafor use in New Zealand
por: Swinn, Tim, et al.
Publicado: (2021)

Plerixafor stem cell mobilization in Japanese children: A post‐marketing study
por: Goto, Hiroaki, et al.
Publicado: (2022)

Development and validation of a predictive model to guide the use of plerixafor in pediatric population
por: Sebastien, Bernard, et al.
Publicado: (2022)

Sickle Cell Anemia and Babesia Infection
por: Beri, Divya, et al.
Publicado: (2021)

1581. Impact of Colonization with Fluoroquinolone-Resistant Enterobacteriaceae on the Risk of Gram-Negative Bacteremia in Hematopoietic Stem Cell Transplant Recipients Who Receive Prophylactic Levofloxacin
por: Satlin, Michael J, et al.
Publicado: (2018)

Plerixafor in non-Hodgkin’s lymphoma patients: a German analysis of time, effort and costs
por: Hübel, Kai, et al.
Publicado: (2018)

P1343: TRANSPLANT OUTCOMES OF LYMPHOMA PATIENTS UNDERGOING STEM CELL MOBILIZATION WITH PLERIXAFOR
por: Gunes, A. K., et al.
Publicado: (2022)

Clinical and molecular epidemiology of human rhinovirus infections in patients with hematologic malignancy
por: Jacobs, Samantha E., et al.
Publicado: (2015)

GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials
por: Dinart, D., et al.
Publicado: (2020)

Plerixafor as a salvage mobilization strategy for haploidentical peripheral blood allogeneic stem cell transplantation
por: Nadeau, Michelle, et al.
Publicado: (2015)

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update
por: Bilgin, Yavuz M
Publicado: (2021)

Plerixafor as a preemptive or salvage therapy for healthy donors with poor mobilization of hematopoietic stem cells
por: Kuang, Pu, et al.
Publicado: (2022)

Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia
por: Roboz, Gail J., et al.
Publicado: (2018)

Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration
por: De Clercq, Erik
Publicado: (2019)

Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients
por: Shumilov, Evgenyi, et al.
Publicado: (2019)

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update [Corrigendum]
Publicado: (2022)

A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome
por: McDermott, David H., et al.
Publicado: (2023)

COVID19 vaccination in adults with sickle cell disease is not associated with increases in rates of pain crisis
por: Friedman, Elana, et al.
Publicado: (2022)

Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma
por: Agarwal, Rishi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_o6tnjvbg63qi5gs9c8hnlhgh7d